Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a
dramatic impact on quality of life, significantly more so than other chronic skin diseases,
such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to
frequent emergency department and inpatient care utilization, and re-hospitalization rates
similar to congestive heart failure. Unfortunately, few treatment options are effective.
There is only one currently FDA-approved treatment, adalimumab, but only 40- 60% respond to
treatment and over 50% lose response within one year . The overarching goal of this pilot
study is to investigate the central hypothesis that oral microbiota transplant therapy(MTT)
alters the gut microbiome in patients with Hidradenitis Suppurativa (HS), influencing
cutaneous microbiota via systemically absorbed gut-derived metabolites.